PDF(Pubmed)
Abstract：
UNASSIGNED: Telomerase is activated or overexpressed in 85-90% of tumors, which maintains the length of telomere and has become an important anti-cancer target. Increasing clinical and preclinical data suggest that telomerase-targeted cancer immunotherapy could achieve effective killing of tumor cells in vivo. This article reviews the research progress of telomerase targeted cancer immunotherapy in clinical and pre-clinical trials, aiming to provide a reference for further clinical research and treatment of cancers.
UNASSIGNED: We investigated the research progress of telomerase immunotherapy in the last 20 years from four electronic databases.
UNASSIGNED: Telomerase-targeted immunotherapies have been developed with the arising of a new era in immuno-oncology, including peptide vaccines, DNA vaccines, dendritic cells (DCs), adoptive cell transfer (ACT) therapies, antibodies, etc. Some of them have been approved for undergoing clinical trials by the Food and Drug Administration (FDA) for the treatment of various cancers, such as pancreatic cancer, non-small cell lung cancer, melanoma, leukaemia. Of all the treatment modalities, vaccines are the primary treatment methods, some of which have been even entered into phase III clinical trials. The main clinical application direction of telomerase vaccine is the combination with other drugs and treatment modalities, including combination with other vaccines targeting human telomerase reverse transcriptase (hTERT), traditional chemotherapy drugs and immunosuppressors. We also summarized the recent findings of immunotherapy targeting hTERT, focusing on various vaccines and the current status of associated clinical trials. We further discussed the advantages, disadvantages and potential developmental directions of various telomerase-targeted immunotherapies.
UNASSIGNED: Telomerase-targeted cancer immunotherapy has promising prospects in improving patient survival expectancy. This review may provide data support and design ideas for all researchers and pharmaceutical enterprises in this field.
UNASSIGNED: We investigated the research progress of telomerase immunotherapy in the last 20 years from four electronic databases.
UNASSIGNED: Telomerase-targeted immunotherapies have been developed with the arising of a new era in immuno-oncology, including peptide vaccines, DNA vaccines, dendritic cells (DCs), adoptive cell transfer (ACT) therapies, antibodies, etc. Some of them have been approved for undergoing clinical trials by the Food and Drug Administration (FDA) for the treatment of various cancers, such as pancreatic cancer, non-small cell lung cancer, melanoma, leukaemia. Of all the treatment modalities, vaccines are the primary treatment methods, some of which have been even entered into phase III clinical trials. The main clinical application direction of telomerase vaccine is the combination with other drugs and treatment modalities, including combination with other vaccines targeting human telomerase reverse transcriptase (hTERT), traditional chemotherapy drugs and immunosuppressors. We also summarized the recent findings of immunotherapy targeting hTERT, focusing on various vaccines and the current status of associated clinical trials. We further discussed the advantages, disadvantages and potential developmental directions of various telomerase-targeted immunotherapies.
UNASSIGNED: Telomerase-targeted cancer immunotherapy has promising prospects in improving patient survival expectancy. This review may provide data support and design ideas for all researchers and pharmaceutical enterprises in this field.
摘要：
■端粒酶在85-90％的肿瘤中被激活或过表达，保持端粒的长度，已成为重要的抗癌靶点。越来越多的临床和临床前数据表明，端粒酶靶向的癌症免疫治疗可以在体内有效杀死肿瘤细胞。本文就端粒酶靶向肿瘤免疫治疗在临床和临床前试验中的研究进展作一综述,旨在为癌症的进一步临床研究和治疗提供参考。
■我们从四个电子数据库中调查了端粒酶免疫治疗近20年的研究进展。
■随着免疫肿瘤学新时代的兴起，端粒酶靶向免疫疗法得到了发展。包括肽疫苗，DNA疫苗,树突状细胞（DC），过继细胞转移（ACT）疗法，抗体，等。其中一些已被食品和药物管理局（FDA）批准接受临床试验，用于治疗各种癌症，比如胰腺癌，非小细胞肺癌,黑色素瘤，白血病.在所有的治疗方式中，疫苗是主要的治疗方法，其中一些甚至已进入III期临床试验。端粒酶疫苗的主要临床应用方向是与其他药物和治疗方式的结合,包括与其他针对人端粒酶逆转录酶（hTERT）的疫苗的组合，传统的化疗药物和免疫抑制剂。我们还总结了针对hTERT的免疫治疗的最新发现，关注各种疫苗和相关临床试验的现状。我们进一步讨论了优势，各种端粒酶靶向免疫疗法的缺点和潜在的发展方向。
■端粒酶靶向癌症免疫治疗在提高患者预期生存率方面具有良好的前景。本综述可为该领域的所有研究人员和制药企业提供数据支持和设计思路。
■我们从四个电子数据库中调查了端粒酶免疫治疗近20年的研究进展。
■随着免疫肿瘤学新时代的兴起，端粒酶靶向免疫疗法得到了发展。包括肽疫苗，DNA疫苗,树突状细胞（DC），过继细胞转移（ACT）疗法，抗体，等。其中一些已被食品和药物管理局（FDA）批准接受临床试验，用于治疗各种癌症，比如胰腺癌，非小细胞肺癌,黑色素瘤，白血病.在所有的治疗方式中，疫苗是主要的治疗方法，其中一些甚至已进入III期临床试验。端粒酶疫苗的主要临床应用方向是与其他药物和治疗方式的结合,包括与其他针对人端粒酶逆转录酶（hTERT）的疫苗的组合，传统的化疗药物和免疫抑制剂。我们还总结了针对hTERT的免疫治疗的最新发现，关注各种疫苗和相关临床试验的现状。我们进一步讨论了优势，各种端粒酶靶向免疫疗法的缺点和潜在的发展方向。
■端粒酶靶向癌症免疫治疗在提高患者预期生存率方面具有良好的前景。本综述可为该领域的所有研究人员和制药企业提供数据支持和设计思路。
